Investigation into Unicycive Therapeutics
Bragar Eagel & Squire is currently looking into potential claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for the benefit of long-term stockholders. This matter stems from a class action complaint, which raises significant concerns about the company's governance and the responsibilities of its board of directors.
Long-Term Stockholders' Inquiries
If you have been a long-term stockholder of Unicycive Therapeutics since March 29, 2024, up until June 27, 2025, and you’re seeking insight into your legal options, Bragar Eagel & Squire encourages you to reach out. You can call partners Brandon Walker or Marion Passmore at (212) 355-4648 to discuss your rights.
Recent Developments within Unicycive
Recently, Unicycive announced difficulties related to its New Drug Application (NDA) for oxylanthanum carbonate (OLC), a treatment aimed at addressing hyperphosphatemia in patients with chronic kidney disease on dialysis. Initial statements from the company portrayed confidence in meeting the regulatory standards set by the U.S. FDA. However, the situation took a turn as it was later disclosed that the company may have overstated its readiness.
Impact of FDA Findings
On June 10, 2025, Unicycive reported that the FDA found deficiencies in the compliance with manufacturing practices from a third-party vendor. This revelation led to substantial financial repercussions, with the company’s stock price plummeting over 40% following the news. Just a few weeks later, on June 30, 2025, the company faced further challenges when the FDA issued a Complete Response Letter in regard to its NDA, highlighting previous compliance issues. This incident saw Unicycive's stock Dive close to 30% further, closing at $4.77 per share.
Next Steps for Investors
For those who identify as long-term shareholders of Unicycive Therapeutics, it is crucial to stay informed about these unfolding events and consider your next steps carefully. If you possess information about the situation or wish to acquire more knowledge about potential claims, connecting with Bragar Eagel & Squire could be beneficial. The firm emphasizes that there is no cost or obligation in reaching out.
About Bragar Eagel & Squire
Bragar Eagel & Squire, P.C. is a well-regarded law firm known for representing both individual and institutional investors in complex litigation matters. They operate in numerous regions and bring a strong emphasis on protecting shareholder interests and rights. For those interested in learning more, the firm invites you to visit their website for additional details.
Contact Information
Investors looking to discuss their rights or seek legal advice can contact:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Frequently Asked Questions
What should Unicycive stockholders know about the investigation?
The investigation seeks to determine if Unicycive's board breached its fiduciary duties to the shareholders.
Who can participate in this legal action?
Long-term stockholders of Unicycive, particularly those between March 29, 2024, and June 27, 2025.
How can I contact Bragar Eagel & Squire for more information?
Investors can call (212) 355-4648 or email investigations@bespc.com for details.
What happened to Unicycive's stock price recently?
Unicycive's stock suffered significant drops due to FDA compliance issues, losing over 40% in one instance and nearly 30% in another.
What does the firm focus on?
Bragar Eagel & Squire specializes in securities and complex litigation on behalf of investors nationwide.
